National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Fingolimod

Synonyms

FINGOLIMOD

Fingolimod

Definitions

An orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively targets and binds to S1PR1 on lymphocytes and causes transient receptor activation followed by S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory M2 phenotype, and modulates their proliferation, morphology, and cytokine release via inhibition of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7).

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C74202

CAS_Registry

162359-55-9

CHEBI_ID

CHEBI:63115

Chemical_Formula

C19H33NO2

code

C74202

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

Contributing_Source

CTRP

FDA

DEFINITION

An orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively targets and binds to S1PR1 on lymphocytes and causes transient receptor activation followed by S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory M2 phenotype, and modulates their proliferation, morphology, and cytokine release via inhibition of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7).

Display_Name

Fingolimod

FDA_UNII_Code

3QN8BYN5QF

FULL_SYN

FINGOLIMOD

Fingolimod

Has_Salt_Form

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C72782

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102500

label

Fingolimod

Legacy Concept Name

Fingolimod

Preferred_Name

Fingolimod

prefixIRI

Thesaurus:C74202

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C1699926

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C308

Delete Subject Author Type Created
No notes to display